# TScan Therapeutics, Inc.: financial statements, quarterly

TCRX · Nasdaq · CIK 1783328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tcrx.md) · [Financials](/companies/tcrx/financials.md) · [Filings](/companies/tcrx/filings.md) · [Insiders](/companies/tcrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tcrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.9](/filings/0000950170-24-124575.md) | [7.2 d](/filings/0000950170-25-033077.md) | [0.6](/filings/0000950170-25-063968.md) | [0.5](/filings/0000950170-25-106919.md) | [1.0](/filings/0001193125-25-275933.md) | [0.7 d](/filings/0001193125-26-089884.md) | [2.2](/filings/0001193125-26-207572.md) | [3.1](/filings/0001193125-26-345749.md) | [2.5](/filings/0001193125-25-275933.md) | [2.6 d](/filings/0001193125-26-089884.md) | [1.0](/filings/0001193125-26-207572.md) | [1.1](/filings/0001193125-26-345749.md) |
| Research and development | $m | [22.7](/filings/0000950170-24-124575.md) | [22.4 d](/filings/0000950170-25-033077.md) | [24.9](/filings/0000950170-25-063968.md) | [26.9](/filings/0000950170-25-106919.md) | [26.3](/filings/0001193125-25-275933.md) | [29.4 d](/filings/0001193125-26-089884.md) | [29.8](/filings/0001193125-26-207572.md) | [32.6](/filings/0001193125-26-345749.md) | [31.7](/filings/0001193125-25-275933.md) | [20.0 d](/filings/0001193125-26-089884.md) | [21.9](/filings/0001193125-26-207572.md) | [23.4](/filings/0001193125-26-345749.md) |
| Operating income | $m | [(24.7)](/filings/0000950170-24-124575.md) | [(21.4) d](/filings/0000950170-25-033077.md) | [(31.4)](/filings/0000950170-25-063968.md) | [(34.1)](/filings/0000950170-25-106919.md) | [(32.6)](/filings/0001193125-25-275933.md) | [(36.7) d](/filings/0001193125-26-089884.md) | [(36.3)](/filings/0001193125-26-207572.md) | [(38.7)](/filings/0001193125-26-345749.md) | [(37.1)](/filings/0001193125-25-275933.md) | [(23.9) d](/filings/0001193125-26-089884.md) | [(29.1)](/filings/0001193125-26-207572.md) | [(30.5)](/filings/0001193125-26-345749.md) |
| Interest expense | $m | [1.0](/filings/0000950170-24-124575.md) | [0.9 d](/filings/0000950170-25-033077.md) | [1.0](/filings/0000950170-25-063968.md) | [1.0](/filings/0000950170-25-106919.md) | [1.0](/filings/0001193125-25-275933.md) | [0.8 d](/filings/0001193125-26-089884.md) | [0.7](/filings/0001193125-26-207572.md) | [0.7](/filings/0001193125-26-345749.md) | [0.7](/filings/0001193125-25-275933.md) | [0.7 d](/filings/0001193125-26-089884.md) | [0.7](/filings/0001193125-26-207572.md) | [0.7](/filings/0001193125-26-345749.md) |
| Net income | $m | [(23.0)](/filings/0000950170-24-124575.md) | [(19.6) d](/filings/0000950170-25-033077.md) | [(30.1)](/filings/0000950170-25-063968.md) | [(31.7)](/filings/0000950170-25-106919.md) | [(29.9)](/filings/0001193125-25-275933.md) | [(35.8) d](/filings/0001193125-26-089884.md) | [(34.1)](/filings/0001193125-26-207572.md) | [(37.0)](/filings/0001193125-26-345749.md) | [(35.7)](/filings/0001193125-25-275933.md) | [(23.0) d](/filings/0001193125-26-089884.md) | [(28.7)](/filings/0001193125-26-207572.md) | [(30.4)](/filings/0001193125-26-345749.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0000950170-24-124575.md) | not reported | [(0.32)](/filings/0000950170-25-063968.md) | [(0.28)](/filings/0000950170-25-106919.md) | [(0.25)](/filings/0001193125-25-275933.md) | not reported | [(0.26)](/filings/0001193125-26-207572.md) | [(0.28)](/filings/0001193125-26-345749.md) | [(0.28)](/filings/0001193125-25-275933.md) | not reported | [(0.22)](/filings/0001193125-26-207572.md) | [(0.23)](/filings/0001193125-26-345749.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0000950170-24-124575.md) | not reported | [(0.32)](/filings/0000950170-25-063968.md) | [(0.28)](/filings/0000950170-25-106919.md) | [(0.25)](/filings/0001193125-25-275933.md) | not reported | [(0.26)](/filings/0001193125-26-207572.md) | [(0.28)](/filings/0001193125-26-345749.md) | [(0.28)](/filings/0001193125-25-275933.md) | not reported | [(0.22)](/filings/0001193125-26-207572.md) | [(0.23)](/filings/0001193125-26-345749.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [155](/filings/0000950170-24-124575.md) | [133](/filings/0000950170-25-033077.md) | [141](/filings/0000950170-25-063968.md) | [242](/filings/0000950170-25-106919.md) | [133](/filings/0001193125-25-275933.md) | [179](/filings/0001193125-26-089884.md) | [154](/filings/0001193125-26-207572.md) | [169](/filings/0001193125-26-345749.md) | [170](/filings/0001193125-25-275933.md) | [152](/filings/0001193125-26-345749.md) | [128](/filings/0001193125-26-207572.md) | [100](/filings/0001193125-26-345749.md) |
| Current assets | $m | [218](/filings/0000950170-23-061533.md) | [194](/filings/0000950170-25-033077.md) | [165](/filings/0000950170-24-058198.md) | [300](/filings/0000950170-24-095066.md) | [274](/filings/0000950170-24-124575.md) | [293](/filings/0001193125-26-089884.md) | [255](/filings/0000950170-25-063968.md) | [221](/filings/0000950170-25-106919.md) | [188](/filings/0001193125-25-275933.md) | [157](/filings/0001193125-26-345749.md) | [133](/filings/0001193125-26-207572.md) | [104](/filings/0001193125-26-345749.md) |
| Total assets | $m | [291](/filings/0000950170-23-061533.md) | [272](/filings/0000950170-25-033077.md) | [241](/filings/0000950170-24-058198.md) | [375](/filings/0000950170-24-095066.md) | [348](/filings/0000950170-24-124575.md) | [371](/filings/0001193125-26-089884.md) | [333](/filings/0000950170-25-063968.md) | [299](/filings/0000950170-25-106919.md) | [262](/filings/0001193125-25-275933.md) | [229](/filings/0001193125-26-345749.md) | [202](/filings/0001193125-26-207572.md) | [171](/filings/0001193125-26-345749.md) |
| Current liabilities | $m | [33.2](/filings/0000950170-23-061533.md) | [29.8](/filings/0000950170-25-033077.md) | [31.5](/filings/0000950170-24-058198.md) | [38.6](/filings/0000950170-24-095066.md) | [28.7](/filings/0000950170-24-124575.md) | [36.0](/filings/0001193125-26-089884.md) | [29.8](/filings/0000950170-25-063968.md) | [31.3](/filings/0000950170-25-106919.md) | [29.2](/filings/0001193125-25-275933.md) | [18.7](/filings/0001193125-26-345749.md) | [20.0](/filings/0001193125-26-207572.md) | [31.0](/filings/0001193125-26-345749.md) |
| Total liabilities | $m | [122](/filings/0000950170-23-061533.md) | [121](/filings/0000950170-25-033077.md) | [118](/filings/0000950170-24-058198.md) | [120](/filings/0000950170-24-095066.md) | [119](/filings/0000950170-24-124575.md) | [130](/filings/0001193125-26-089884.md) | [123](/filings/0000950170-25-063968.md) | [122](/filings/0000950170-25-106919.md) | [118](/filings/0001193125-25-275933.md) | [106](/filings/0001193125-26-345749.md) | [105](/filings/0001193125-26-207572.md) | [102](/filings/0001193125-26-345749.md) |
| Long-term debt | $m | [28.8](/filings/0000950170-23-061533.md) | [26.7](/filings/0000950170-25-033077.md) | [23.4](/filings/0000950170-24-058198.md) | [20.1](/filings/0000950170-24-095066.md) | [30.6](/filings/0000950170-24-124575.md) | [32.1](/filings/0001193125-26-089884.md) | [32.2](/filings/0000950170-25-063968.md) | [32.3](/filings/0000950170-25-106919.md) | [32.4](/filings/0001193125-25-275933.md) | [32.5](/filings/0001193125-26-345749.md) | [32.7](/filings/0001193125-26-207572.md) | [21.1](/filings/0001193125-26-345749.md) |
| Current portion of debt | $m | [1.1](/filings/0000950170-23-061533.md) | [3.3](/filings/0000950170-25-033077.md) | [6.8](/filings/0000950170-24-058198.md) | [10.3](/filings/0000950170-24-095066.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [11.7](/filings/0001193125-26-345749.md) |
| Shareholders' equity | $m | [169](/filings/0000950170-24-124575.md) | [151](/filings/0001193125-26-089884.md) | [123](/filings/0000950170-25-106919.md) | [255](/filings/0001193125-25-275933.md) | [229](/filings/0001193125-25-275933.md) | [241](/filings/0001193125-26-345749.md) | [210](/filings/0001193125-26-345749.md) | [177](/filings/0001193125-26-345749.md) | [144](/filings/0001193125-25-275933.md) | [123](/filings/0001193125-26-345749.md) | [96.9](/filings/0001193125-26-345749.md) | [69.0](/filings/0001193125-26-345749.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [8.0 d](/filings/0000950170-24-124575.md) | [(23.8) d](/filings/0000950170-25-033077.md) | [(29.3)](/filings/0000950170-25-063968.md) | [(26.2) d](/filings/0000950170-25-106919.md) | [(27.9) d](/filings/0001193125-25-275933.md) | [(27.4) d](/filings/0001193125-26-089884.md) | [(37.6)](/filings/0001193125-26-207572.md) | [(33.3) d](/filings/0001193125-26-345749.md) | [(32.5) d](/filings/0001193125-25-275933.md) | [(32.0) d](/filings/0001193125-26-089884.md) | [(24.3)](/filings/0001193125-26-207572.md) | [(27.5) d](/filings/0001193125-26-345749.md) |
| Capital expenditure | $m | [1.4 d](/filings/0000950170-24-124575.md) | [0.5 d](/filings/0000950170-25-033077.md) | [0.7](/filings/0000950170-25-063968.md) | [0.9 d](/filings/0000950170-25-106919.md) | [1.4 d](/filings/0001193125-25-275933.md) | [0.9 d](/filings/0001193125-26-089884.md) | [1.5](/filings/0001193125-26-207572.md) | [1.3 d](/filings/0001193125-26-345749.md) | [1.4 d](/filings/0001193125-25-275933.md) | [0.2 d](/filings/0001193125-26-089884.md) | [0.1](/filings/0001193125-26-207572.md) | [0.5 d](/filings/0001193125-26-345749.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.1](/filings/0000950170-23-061533.md) | [24.2](/filings/0000950170-24-058198.md) | [47.2](/filings/0000950170-24-095066.md) | [94.8](/filings/0000950170-24-124575.md) | [94.9](/filings/0000950170-25-063968.md) | [113](/filings/0000950170-25-106919.md) | [119](/filings/0001193125-25-275933.md) | [130](/filings/0001193125-26-207572.md) | [130](/filings/0001193125-26-345749.md) | [130](/filings/0001193125-25-275933.md) | [130](/filings/0001193125-26-207572.md) | [130](/filings/0001193125-26-345749.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 23,976,942 at 2022-03-04, from the cover of the [10-K filed 2022-03-09](/filings/0000950170-22-003175.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.